Metabolic syndrome and cardiovascular disease
- PMID: 16280341
- DOI: 10.1177/0269881105058375
Metabolic syndrome and cardiovascular disease
Abstract
Metabolic syndrome is a constellation of clinical findings that identify individuals at higher than normal risk of developing diabetes mellitus or cardiovascular disease. There are two principal definitions, one emerging from the American National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, and the other from the World Health Organization. Both definitions share the common elements of abdominal obesity, hypertriglyceridaemia, low HDL-cholesterol, hypertension and abnormal glucose regulation. The syndrome is relatively common across continents, and also among those without marked obesity. It is even more common among patients with major mental health disorders such as schizophrenia. Metabolic syndrome can be used to assess risk for cardiovascular disorder and death, and is an alternative to Framingham Risk Calculations. C-reactive protein may play an additional role in risk prediction. Ongoing monitoring for all components of the metabolic syndrome is necessary. Individuals at high risk require multimodal interventions, including lifestyle interventions and targeted medications as appropriate.
Similar articles
-
Prognostic impact of metabolic syndrome by different definitions in a population with high prevalence of obesity and diabetes: the Strong Heart Study.Diabetes Care. 2007 Jul;30(7):1851-6. doi: 10.2337/dc06-2152. Epub 2007 Apr 17. Diabetes Care. 2007. PMID: 17440172
-
Differences in traditional and emerging cardiovascular risk factors of subjects discordantly classified by metabolic syndrome definitions of the International Diabetes Federation and the National Cholesterol Education Program.Nutr Metab Cardiovasc Dis. 2009 Jul;19(6):417-22. doi: 10.1016/j.numecd.2008.07.010. Epub 2008 Sep 25. Nutr Metab Cardiovasc Dis. 2009. PMID: 18819785
-
Metabolic and lifestyle issues and severe mental illness--new connections to well-being?J Psychopharmacol. 2005 Nov;19(6 Suppl):188-22. J Psychopharmacol. 2005. PMID: 19886294 No abstract available.
-
The metabolic syndrome and cardiovascular disease: part 2.Prev Cardiol. 2008 Fall;11(4):223-9. doi: 10.1111/j.1751-7141.2008.00002.x. Prev Cardiol. 2008. PMID: 19476575 Review.
-
Effect of a lifestyle intervention in patients with abnormal liver enzymes and metabolic risk factors.J Gastroenterol Hepatol. 2009 Mar;24(3):399-407. doi: 10.1111/j.1440-1746.2008.05694.x. Epub 2008 Dec 2. J Gastroenterol Hepatol. 2009. PMID: 19067776 Clinical Trial.
Cited by
-
Drug-emergent metabolic syndrome in patients with schizophrenia receiving atypical (second-generation) antipsychotics.Indian J Psychiatry. 2011 Apr;53(2):128-33. doi: 10.4103/0019-5545.82537. Indian J Psychiatry. 2011. PMID: 21772644 Free PMC article.
-
Prevalence of metabolic syndrome among patients with schizophrenia in Ethiopia.BMC Psychiatry. 2021 Dec 11;21(1):620. doi: 10.1186/s12888-021-03631-2. BMC Psychiatry. 2021. PMID: 34895175 Free PMC article.
-
Prevalence of metabolic syndrome among patients with schizophrenia in Palestine.BMC Psychiatry. 2012 Dec 27;12:235. doi: 10.1186/1471-244X-12-235. BMC Psychiatry. 2012. PMID: 23270504 Free PMC article.
-
Metabolic syndrome in people with schizophrenia: a review.World Psychiatry. 2009 Feb;8(1):15-22. doi: 10.1002/j.2051-5545.2009.tb00199.x. World Psychiatry. 2009. PMID: 19293950 Free PMC article.
-
Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder.Clin Drug Investig. 2011;31(7):455-82. doi: 10.2165/11589060-000000000-00000. Clin Drug Investig. 2011. PMID: 21495734 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials